Notably, gilteritinib, which is used clinically to treat FLT3-positive AML, was shown to have a more synergistic effect with palbociclib compared to quizartinib.[40] Palbociclib treatment not only enhances the inhibitory effects of FLT3 inhibitors in leukemia cells but also helps to overcome resistance associated with FLT3 inhibitors alone, suggesting targeting both CDK6 and FLT3 could lead to more robust and sustained antileukemic effects. Here, CDK6 is linked to acute myeloid leukemia.